[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

37

1 Dr. Moskowitz.
2 If you recall when we were deliberating on
3 the NIH strategic plan and talked about vaccine
4 development, it was clear that vaccines lived in a
5 world of science and they lived in a world that was
6 where issues such as pathogenesis, such as immunology,
7 such as virology, were critical components of their
8 development and design. This is very much in the same
9 mold as that.
10 Now, let me go to the next slide, please.
11 The tasks of this working group are as follows: to
12 assess the scientific database that exists now and the
13 current directions that are in place and decide if
14 this is, in fact, the way to proceed.
15 There are clearly many gaps in our
16 scientific knowledge and in vaccine development, in
17 particular, but there are also a number of
18 opportunities. And the questions are how to put these
19 two issues together.
20 The studies that need to be performed
21 combined with the obvious need and so on and so forth
22 require that this working group be involved not only
NEAL R. GROSS
COURT REPORTERS AND TRANSCRISERS
1323 RHODE ISLAND AVENUE, N.W.
[phone] WASHINGTON, D.C. 20005 [phone]